Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB048C in Advanced Solid Tumors
NCT07192120Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of MHB048C in solid tumor (advanced stage), metastatic castration-resistant prostate cancer (mCRPC), sponsored by Minghui Pharmaceutical, Inc.. Started Jan 2026; status: recruiting.
02
Drugs
MHB048C
03
Conditions
solid tumor (advanced stage)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07192120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192120.